11-12 September 2018 //  Lancaster Royal Hotel, London


Pierre Heimendinger

Pierre Heimendinger

PharmD, VP Process Development, TxCell

Pierre Heimendinger, 55, is appointed VP Process Development. Pierre has over 31 years of experience in the pharmaceutical industry and specifically in the field of biotechnology, immunotherapy, vaccines, plasma-derived medicinal products and viral vectors. Pierre gained his experience of manufacturing processes of development and analytical methods of control through numerous positions he has held in research and development, industrialization processes, production and quality control for products for Phase 1, 2, and 3 clinical trials and for commercial products on the market. He has improved the robustness of products as well as control strategies as well as enrolling new drugs in clinical trials as guidelines alter. He has achieved this by implementing quality by design and process analytical technology by the development of regulatory proceedings. Before joining TxCell in 2015, Pierre held a senior director position at Transgene SA where he led the pharmaceutical development team and was responsible for the development of new processes, analytical methods and technology transfer immunotherapy treatments using viral vectors. He started his career at Sanofi Pasteur where he held several positions in R&D and production, then at Mérieux and Octapharma. Pierre has a doctor of pharmacy degree complemented by a postgraduate in cellular and genetic toxicology from the University of Paris VII.


2017 Speakers

"It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance."

Bertrand Alexandre, Director, Marketing Europe, Celyad